THE UROLOGY FOUNDATION THE UROLOGY FOUNDATION TRUSTEES, REPORT & FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 2023 "THE WAY AHEAD 2023-2025" GY OUN AT ON Ahead 2023-2025 theurolo9yfoundatlon.or9 Contents Statcmcnt from thc Chair.................................................................................................................................... Overview of the year.......................................................................................................................................... Staternenl from the Chief Executive, Rebecca Porta.......................................................................................... StsteTnent from the Chief Executive, Rebecca Porta {contiKued)....................................................................... Objectives and Activities Our Vision and Mission.. OUT Aims............................................................................................................................................................ Our Values.......................................................................................................................................................... Whatwe do.......................................................................................................................................-.......-.......-. Public Benefit..................................................................................................................................................... Graiits policy....................................................................................................................................................... Achievements and Performancein2023...-............-..........-.......-.......................-............ Our Strategy.. The Way Ahead 2023-2025............................................................................................... Our Re5eaich Pro¥ramme........................................................................................................................ Improving knowledge and skills through education and training........................................................... Financial Review. Finaiicial Results of Activitie5 & Events.......................................................................................................... 19 Fundraising....................................................................................................................................................... R¢serv¢s & Liquidity Policy............................................................................................................................. 20 Ststement of going concem.............................................................................................................................. 21 Investments Policy............................................................................................................................................ 21 Remuneration policy......................................................................................................................................... Pensions policy................................................................................................................................................. Equal opportunitics and divcrsiry policy.. Principal risks at]d uncertainties....................................................................................................................... Structure, Governance & Management....................................................................... 23 Charity Govemance Code................................................................................................................................. 23 Trnstee RecniittnenL Training and Lnduction................................................................................................... 23 Appointment & Election................................................................................................................................... 23 Rclationships with Rclatcd Parti¢s .24 Representation on Other Bodies....................................................................................................................... 24 Reference and administrative details......................................................................... 25 Trustees................................................... .25 21 Regi%tered Office.............................................................................................................................................. 25 Auditors............................................................................................................................................................ 25 Trustees, & Directors, Responsibilities in the Preparation of Financial Statements . 26 Auditor.............................................................................................................................................................. 26 Statement as to disclosure of infomiation to the auditoi .................................................................................. 26 The Urology Foundation annual report & financial statements 2023 Statement from the Chair Overview of the year Welcome to our Annual Report for 2023. 1 in 2 people will suffer from a urological disease or condition in their lifetime. This includes urological cancers - prostate, kidneyi bladder and male reproductive cancers - and non-malignant conditions including incontinence, urinary tract infections and kidney stones. People diagnosed and living with these urological cancer5 and conditions seek information, support and interventions to help navigate the health and social care system and the challenges of everyday life. We are the only charity in the UK representing the entire spectrum of urology health and disease and through our investment in world class research, training and education proqrammes, raising awarenes5 and driving policy change, we are in the unique position of being the "voice" of the urology community. This year we launched our new strategy "The Way Ahead 2023-2025" The strategy is a bold, exciting and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical communityi nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our Scientific and medical communities and, guided by research outcome5, to drive change. At the heart of our strategy are patients and their families.. involving and working with people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a "voice" in shaping future research agendas and priority areas. "The Way Ahead 2023-2025" strategy sets out eight prioritie5: Priority 1: Significantly accelerate the progress and breakthroughs in urological research. Prlority 2: Invest in our scientific and medical communities, support early career researchers and fund new, innovative ideas. Prlorlty 3: Facilitate collaborations and partnerships with individual research leaders and research institutes, charities, industry and partners who share our common goals. Priority 4: Drive change in behaviours, beliefs, policy and practice as a result of research outcomes. Priority 5: Campaign for further investment in research through working wth patients, their families, health and social care professionals, researchers, policy makers, charities, government, industry, funding bodies and those wth an interest in research. Priority 6.. Place people affected by urological disease at the heart of research, ensuing they are involved at all stages of research design, delivery, analysis and dissernination. Priority 7: Give a voice to the people affected by or at risk of urological disease ensuing they have the opportunity to be heard, to influence and drive change. Prlorlty 8: Transforming The Urology Foundation- ensuring we can build on our success and deliver our objectives, for the benefit of our stakeholders. We are ambitlOU5 for the future and what can be achieved. Ensuring patients and their farnilies have better outcomes, live longer, and with a better quality of life, remains at the heart of our work. Mary Garthwaite. Chair The Urology Foundation annual report & financial statements 2023 Statement from the Chief Executive, Rebecca Porta This has been another successful year for the Foundation thanks to the support and commitment of our stakeholders the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters. We awarded eight new Research and Innovation Projects and five Small Project Grants covering kidney and prostate cancer5, urinary tract infections, urothelial cancer and the management of Haematuria. We introduced new training and career development opportunities, study ané travel grants to support our scientific and medical communities and encourage the "rising stars" in urology. The TUF Trials Unit IThUI, a partnership with The Centre for Healthcare Randomised Trials ICHaRT at the University of Aberdeen delivered impressive results, supporting urologists from across the UK to put forward their ideas and application5 for research. rru has already helped secure an impressive £6.1 million in funding for the research community f rom our initial investment of £180,(KK)1£60,000 per annuml. 1 in 2 of us will be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life. Throughout the year we prowded media spokespeople, ran campaigns and awareness events, presented at conferences, met with decision makers and influencers and worked with a wide range of stakeholders to drive policy change. A key focus this year has been prostate cancer and bladder health wth opportunities to attend Roundtables and contribute to discussions and recommendations on the care pathway and improving outcomes. Awareness highlights include the annual Urology Awareness Month, World Continence Week, a 'Catheter Care Challenge" at the House of Commons, a Parliamentary Reception and a series of community-ba5ed events encouraging anyone concerned by 'blood in pee" to contact their GP practice. This was part of the NHS England 'Help Us, Help You" symptom awareness campaign. In November we were deli£hted to welcome our first Director of Communications and Policy, Laura Thorne to help drive forward our awareness, campaigning and policy programme. As part of our commitment to put our patient community at the centre of everything we do, we launched our Patient and Public Involvement Programme to bring together researchers, patients, carers and those with an interest in urology. The Programme offers an opportunity to influence and shape research including planning, design, management, evaluation and communication and identifying priorities. Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the gener051ty of our wonderful supporters. Income rose by over 9.6% from £1,355,713 in 2022 to £1,470,272 in 2023. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diverslfied, sustainable sources of incorne. Sincere thanks to all those who have sUPPOrted us. The Urology Foundation annual report & financial statements 2023 Statement from the Chief Executive, Rebecca Porta (continued) It is two years since l joined The Uroloqy Foundation as Chief Executive ané as each month passes my ambition for what I want the Foundation to achieve continues to grow. "The Way Ahead 2023-2025" sets out our ambitions and goals for the future and already we are making great progress towards the eight priorities outlined in the strategy. The aim is to improve the outlook for people affected by urological cancers and conditions ensuring they have better outcomes and a better quality of life. I hope that you will join me in thi5 important and exciting joumey. Rebecca Porta, Chief Executive The Urology Foundation annual report & financial statements 2023 Objectives and Activities The Urology Foundation's objects are to: "Advance, promote, encourage, develop and improve the study and knowledge of urology* urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to as51St in the funding, instruction and support of persons and institutions engaged or involved in urological research work. Our Vision and Mission We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives. Our mission is to improve survival and quality of life for urology patient5 through research and training, so patients receive the best possible treatment and care and fewer lives are devastated. Our Aims The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnos15, treatment and management of urological disease and the nation's urology care. We rely on donation5 from individuals, trusts and foundations, and f rom cornpanies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions. The Foundation is governed by the rules and regulations set down in its company memorandLJm and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009. Our Values In undertaking our remit we are: Arnbitious to see UK urology care, treatment and practice is the best in the world. Dedicdted to beating all urology diseases through research and training. Proud of working in urology and committed to transforming the lives of people with a urology condition. Collaborative., working with researchers, urologists, nurses and health care professionals, influencers and decision makers, charity partners, patients and their families we are improving the nation's urology care. What we do We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core. The Urology Foundation annual report & financial statements 2023 Awareness campaign5 such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms. Public Benefit The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees, annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to: Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnos15 and method of treatment of this disease and by publishing the useful result5 of such research; Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care. Such other purpose5 for the benefit of the community as shall be exclusively charitable as the tru5tee5 from time to time shall decide. In addition, the charity prowdes information on urological cancers and conditions, raises awarene55, campaigns and drives policy change. Grants policy The Foundation advertises its programmes and awards on its website, through its professional e- newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee ISECI and Review Panel. The charity is a member of the Association of Medical Research Charities IAMRCI and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research INIHRI non-commercial Partner. Research studie5 funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network ICRNI support subject to meeting the standard study eligibility criteria. The Urology Foundation annual report & financial statements 2023 Achievements and Performance in 2023 1. Our Strategy: The Way Ahead 2023-2025 In April our new strategy "The Way Ahead 2023-2025" was launched. The strategy is a bold, exciting and ambitious wsion. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and inf luencers, charity and industry partners and 5UPPOrter5 our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our Kientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families.. involving and working th people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a 'voice" in shaping future research agendas and priority areas. "The Way Ahead 2023-2025" strategy sets Out eight priorities: Prlorlty 1. Significantly accelerate the progress of urological research Priority 2. Invest in our scientific and medical communities Priority 3. Facilitate collaborations and partnerships Priority 4. Drive change as a result of research outcomes Priority 5. Campaign for further investment in research Priority 6. Place people affected by urological disease at the heart of research Prlority 7. Give a voice to the people affected by or at risk of urological disease Priority 8. Transforming The Urology Foundation. 2. Our Research Programme Innovation & Research A¥Yards Our Innovation & Research Award fund5 projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either lal aim to create innovative treatments or devices, Ibl aim to deliver innovative care pathways or Icl aim to use innovative research techniques or methods. We are pleased to reFX)rt that eight award5 totalling £431,592 were made in 2023 lin 2022 there were 8 awards totalling £375,096). The eight projects were: act of bod com osition on atients with advanced rostate cancer: The main treatment for advanced pr05tate cancer 15 androgen deprivation therapy IADTI, which lower5 the male hormone called testOSterone. ADT stops prostate cancer growth, but can cause men to lose muscle and to gain fat. This can make men weaker reducing mobility and quality of life. The STAMPEDE trial has studied more than 12,000 men with advanced prostate cancer, testing different combinations of treatments. This project wll use image5 from these men to look at how muscle and fat change wth different combinations of ADT. It will determine if muscle and fat distributions are linked to how well the treatment works and if patients experience greater side-effects. This work will be the world's largest study of body changes in men with advanced prostate cancer. The results will allow us to understand how different treatments act to drive these changes, enabling tailoring treatment to the individual. Usin a livin model of the human bladder to stud Urina Tract Infections UTIS This project will use a living model of the human bladder to study how antimicrobial resistance IAMRI develops during the treatment of urinary tract infection IUTlsl and to study the effects AMR mutations have on Escherichia coli, the most common bug in UTIS. It will use antibiotics recommended for the treatment of UTIS, with E. coli isolated from the urine of patients with UTIS. The data produced in this study will be used as an evidence base to guide the sustainable use of antibiotics for the treatment of UTIS. Additionally, the researchers will generate a database of possible mutation5 which can arise during antibiotic therapy for UTIS and the corresponding effect on the activity of an antibioticlsl. This will The Urology Foundation annual report & financial statements 2023 improve understanding of how the use of antibiotics in humans directly affects the development of MR, leading to improved patient outcomes and reduced healthcare and economic burdens. Investi atin Immune Primin Interventions in Kidne Cancer: Worldwide, over 40,0000 people are diagnosed with a kidney tumour every year. An operation to remove the tumour is currently the only way to completely cure the cancer. This operation is associated with the risks of having major surgery. There are several new treatments which don't involve surgery called ablation treatments lincluding freezing and radiotherapy) which can destroy kidney tumours. The first aim of this project is to find out if any of these ablation treatments can increase the activity of our immune system. A more active immune system has been shown to lead to better results for patients. The second aim will see if changes in the immune system, detectable in a blood test can be used to monitor patients, to tell if the tumour wll grow quickly or slowly. Both these aims could reduce the number of patients undergoing major surgery and the risks associated with it. DESNT biomarker for the rediction of rostate cancer outcomes.. This study 15 developing a test to identify more aggressive cancer that can be used by hospitals, based on patterns of genes being turned on or off in cancer cells at an early stage of the disease. In this project, prostate cancer t155ue, from patients who have had their whole prostate surgically removed to treat their cancer, is compared to the results obtained from their urine and biopsy samples. The researchers wll measure whether genes are switched off or on for all genes in urine, biopsy material and whole prostate samples. They have also collected tissue and genetic information from a separate group of patients with multiple, separate tumour5 Wlthin their prostate and are aiming to look at genetlc similarities and differences between these tumours. Through analysis of the cell markers, they hope to determine classifications that pick up on agqres5iYe cancers. This study wll prowde a greater understanding of how a test of cancer aggressiveness actually works, bringing it closer to being used as a test in clinical use to help patients make decisions about their treatment. How Oestro en or lack of affects the susce tibilit of st-meno ausal women to recurrent urina tract infections: Urinary tract infections IUTlsl are common in post-menopausal women. Treatment is usually antibiotlcs, but re-infections are problematic often resulting in multi-drug resistant bacteria. It is known that women prescribed vaginal oestrogen creams by their doctor have reduced susceptibility to re-infections, but it is not really understood why. The research proposition is that oestrogen treatment alters the physical structure of genetic material or DNA, which helps protect the urinary tract from infection. The project will use samples from postmenopausal women who have either been prescribed vaginal oestrogen or not, and compare the DNA structures of key genes functioning to protect the urinary tlSsues from bacterial infections. Results will provide better knowledge of how oestrogen helps reduce UTIS and support the development of non-antibiotic UTI therapies, including oestrogen mimics, to reduce antibiotic use. A Postal Pilot Stud for a National L nch S ndrome Urothelial Cancer Screenin Pro ramme.. Newcastle University has designed a urine-based cancer test (the Newcastle MSI-Plus assayi. This test identifies characteristic changes in urine samples when there is a cancer in the urinary tract that has been caused by Lynch syndrome, an inherited condition associated with an increased risk of urinary tract cancer. The project aims to establish if this test could become a screening test for urinary tract cancers for individuals with Lynch Syndrome. Researchers will collect urine samples from a minimum of 1W healthy individuals with Lynch Syndrome. They expect that most of these tests will be 'negative' or 'normal' and this sample collection will provide proof that healthy individuals Wlth Lynch Syndrome get an accurate result. They will a150 collect urine samples frorn patients known to have a urinary tract cancer to gather data about the ability of the urine test to pick up these cancers within urine. Ex vivo real-time anal sis of radical rostatectom rnar ins usin fluorescence confocal mTcrosco FCM L. One of the most common curative treatment options for localised prostate cancer is radical prostatectomy IRPI,. a keyhole operation to remove the whole prostate. In some cases, cancer extends very close to the surface of the prostate Ithe 'margin'l and there is a risk of some cancer The Urology Foundation annual report & financial statements 2023 being left behind after RP. Leaving cancer behind may mean it could spread, potentially leading to earlier death. There is currently no accepted technique to test the margins for cancer during RP. This study will test a new technology called fluorescence confocal microscopy IFCMI on the prostate immediately after it is removed during RP. We hope to show that FCM is as accurate as a pathologist in detecting cancer at the surgical margins and, in the future, be used to guide surgeons to remove areas of cancer that have been missed. We are grateful to the John Black Charitable Foundation for their funding for this award. Au mentin the efficac of sonod namic thera ainst metastatic castration-resistant rostate cancer This project will form the b351S toward5 the design and development of new combination treatments with significantly improved therapeutic outcomes for prostate cancer. The team has developed a treatment called sonodynamic therapy utilizinq sound waves and small particles that can eradicate tumours within the prostate in a targeted and minimally invasive manner, with minimum side effects. A large proportion of patients develop prostate cancer types that are very aggressive and difficult to treat with existing therapies. These types of cancer also exhibit relatively increased resistance to sonodynamic therapy, and a potential resistance mechanism that lowers the efficacy of this therapeutic approach has been identified. This research will investigate what prostate cancer types are equipped with the newly discovered mechanism of resistance. Then, it will investigate the efficiency of a non-toxic agent to reduce any relative resistance phenomena to sonodynamic therapy J as well as to radiotherapy and certain chemotherapies. We are grateful to the John Black Charitable Foundation for their funding for this award. Smaller Reseorch Projects Fund The Smaller Research Projects fund is focused on improwng treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly Iwithin 2 years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care. We are pleased to report that five awards totalling E50,000 were made in 2023 lin 2022 there were four awards totalling £40,000). The projects were: A UK multi-centre validation of the novel TARGET scoring system for detecting in-field recurrences after focal therapy for prostate cancer. Improving ways of detecting susceptibility to myocardial Iheartl injury after kidney cancer Surgery. Reducing the Morbidity of Radical Prostatectomy - helping men to regain their erections after surgery for prostate cancer. What a "good improvement" looks like post BPH Surgery: The patients, Perspective. Investigating the barriers to inclusivity in prostate cancer and exercise research within the NHS. A £10,000 award was also made to BURST (British Urology Researchers in Surgical Training), who are a UK-based research collaborative that designs and delivers large-scale research studies in urology, for their study: Ward Admission of Symptomatic Haematuria: An Observational multicentre sTudy IWASHOUTI. Strotegic research funding In 2023 the Foundation awarded a grant of £167,000 to Professor Kelly of UCL, for his research 'Developing algorithms from biometric data to predict complications occurring in patients during and after chemotherapy (HALO Trakl., The HALO Trak study follows on from research emanating from the IROC Trial, which established that robot-assisted bladder cancer surgery reduced time spent in hospital, reduced readmissions, and led to better levels of fitness and a quality of life. It also showed that there was a striking reduction in blood clots in patients receI￿n9 robotic surgery; indicating a safe surgery with patients benefiting from far less complications, early mobilisation and a quicker return to normal life. 10 The Urology Foundation annual report & financial statements 2023 The HALO-Trak study is examining ongoing recovery after surgery using smart, wearable tracking devices to monitor patients remotely J to assess whether a decline in fitness signifwng a potential relapse or recurrence of cancer can be detected through biometric readings. We are grateful to the Champniss Foundation and the Champniss Charitable Foundation for their joint funding of this research. The TUF Trials Unit In 2020 the TUF Trials Unit ITTUI launched in partnership with The Centre for Healthcare Randomised Trials ICHaRTI at the University of Aberdeen. The unit is led by Professor Graeme MacLennan, a medical statistician and Professor James N'DOW, a consultant urologist. The role of the Thu is to identify promising and important research ideas from urology units and provide a team of medical investigators to bring those ideas to fruition. Thi5 approach enables more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues. Successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in treatment and care. With an initial investment of £180,000 IC60,000 per annuml we are pleased to report the Thu has leveraged this funding to secure an impressive £6.1 million in fundinq from the National Institute of Health and Social Care INIHRI to conduct three large-scale, multi-centre trials across the United Kingdom (PARTIAL, ELIPSE, The FOLLOW UP Study). Each of these 5tudie5 addresses major gaps in the evidence base for prostate and kidney cancer and findings wll feed directly into national and international guidelines when completed. Moreover, this infrastructure funding has suptx)rted more urologists to put forward their idea5 for clinical research. The TTU ha5 worked c105ely with 17 chief investigators Iclsl f rom all acr05S the UK to support the workup of 15 submitted grant applications, currently four being reviewed by funders, and four more in preparation for early 2024 submission. The scale of applications varies, the combined amount 15 over £15 million, but every application is multicentre, requiring clinical trials unit expertise for design and delivery if successful. The clinical areas cover the four streams of urology health that The Urology Foundation supports research in Iprostate, kidney, bladder, male reproductive organsl. The research questions range from early phase research on rnedical device development through to natural experiments evaluating follow-up care after prostate cancer treatment. The research managers have prepared applications and financial details for nine distinct funding platforms, greatly easing the administrative burden on Cls, letting them concentrate on the scientific aspect of applications. The TTU has made a significant impact in advancing urology research over the past three year5 and the charity of proud to have played an imwrtant part in its success. TUF Grant Management System The charity currently has over 70 active grants and awards. In 2023 it was agreed that a Grants Management System be implemented to enable a more comprehensive l streamlined tracking of the status of the existing grants. The system will also enable reporting on awards across the four nations, regions, disease areas etc. The database could provide historical data for comparison, and also make it easier to collect information on research results and impact. A bespoke system has been developed the TUF Grant Tracker facilitates the recording of applications, donors, recipients, reviewers, timelines, deliverable outputs, payments, and liabilities for each grant. Patient and Public Involvement (PPI) Programme Individuals with experience of living with a disease or condition, or having significant others with a disease or condition, can bring substantial benefit and insight to charities. More and more charities are actively incorporating their experiences into conversations about the design of services, awarene55 programmes and medical research. The Urology Foundation annual report & financial statements 2023 During the year the charity launched its Patient and Public Involvement IPPII programme. The Programme will play a key role in acting as a bridge between the research community and people affected by urological cancers and conditions. The Programme is overseen by a PPI Development Board members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgowl, Hannah Warren (Trustee of The Urology Foundationl, Helen Lake (Urology Nurse) and Su5annah La-Touche (Urology Consultant at St George's University Hospital). A recruitment drive and series of events and webinars are scheduled for 2024. Our Research Strategy Building on our achievements, we are developing our research strategy which will improve urological health and transform lives through research over the next five years. We are consulting wth researchers, clinicians, nurses, allied healthcare professionals, decision makers and inf luencers, charity and industry partners, patients and their familie5 as well as those with an interest in urology to help inform our strategy and identify key areas from specific disease areas to health inequalities, prevention measures and treatments to training and improving care pathways. The strategy will launch in 2024. 3. Improving knowledge and skills through education and training Fellowsh7PS Fellowships enhance urological training, education, knowledge transfer and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. The Foundation offer5 a variety of different Fellowship opportunities. David Thomp50n Fellowship The David Thompson Fellowships are worth up to £35,000 per fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of specialty. Successful candidates will act a5 Ambassadors promoting best practice and sharing knowledge amongst their own team, hospital and wider urology community. 2023 was the inaugural year of the awards. The standard of applications was exceptionally high and a decision was made to award four Fellowships: Andrew Deytrikh, currently working in Sheffield, who will visit the University of British Columbia hospital in Vancouver, to learn more about robotlc surgery for kidney & testicular cancer patients. Clare O'connell, currently training in Dublin, who will visit University of Toronto to learn more about robotic surgery for kidney, bladder Et testicular cancer patient5. Eoin Dineen, currently at UCL, who will visit the Peter Maccallum Cancer Centre in Melbourne to undertake Prostate cancer surgery & research. Stefanie Croghan, currently in Dublin, who wll undertake Newcastle Endourology Fellowship at the Freeman Hospltal to learn more about Endourology and stone disease. We are grateful to the Thompson Family Charltable Trust for enabling these Fellowshlps. 12 The Urology Foundation annual report & financial statements 2023 Malcolm Coptcoot Travelling Fellowship The Malcolm Coptcoat Fellowship, worth £5,(H)O, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2023, its inaugural year, the Fellowship was awarded to Miss Eleanor Zimmerman, an ST6 Urology Specialist Registrar training at the Freeman Hospital, Newcastle. She will visit The Kulkarni Institute in Pune, India, a world-renowned centre for genito-urethral reconstruction, in particular urethroplasty. This high-volume unit performs in excess of 500 urethroplasties per year, with referrals received from not just across India, but also internationally. The unit regularly performs complex cases that are rarely geen or attempted in the UK, and the international training Professor Kulkarni and Dr Joshi offer is highly regarded and respected globally. TUFIUrolink Fellowships The TUFIUrolink Fellowships, worth up to £1,5CN), are open to those senior level trainees who have completed their FRCS (Uroll, enabling them to experience working in Low or Middle Income ILMICI countries. The Fellowships help develop urological services in those countries as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than $1,135 a year. In 2023 four awards were made- Katie Brodie, a Urology ST6 at the Western General Hospital, Edinburgh Rory Ferguson, a Urology ST3 at Royal Cornwall Hospitals NHS Trust Wilson To, a Urology ST7 at Great Ormond Street Hospital for Children Danielle Whiting, a Urology ST6 at Royal Surrey County Hospital All four will be visiting the Kilimanjaro Christian Medical Centre IKCMCI in Tanzania, to provide a mixture of teaching, training and hands-on surgery. Support for urology trainees and urology nurses Keith Yeates Medal/Ralph Shackman prize The Medal and prize is conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2023 Dr Ben Odusaya, a trainee at Bolton NHS Foundation Trust, won the medal and the Shackman travelling fellowship worth £2,000. He will use the opportunity to attend a cadaveric masterclas5 in the use of HOLEP (Holmium laser enucleation of the prostatel, a treatment for people with benign prostatic hyperplasia IBPHI. Nurse education and training We are committed to ensuring urology nurse5 and allied healthcare profe55ionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician. TUF'S first Nurse Bursary, worth £2,000, was awarded to Catherine Borrington, a senior staff nurse at The Royal Oldham Hospital who is attending the PG Certificate in Urology at Edge Hill University. Catherine's aspiration is to become a Urology Clinical Nurse Specialist, supporting patients with benign and cancer diagnoses on treatment options and patient education, and helping to alleviate the consultant workload. We are grateful to the Charles Reynolds Foundation for funding these awards. 13 The Urology Foundation annual report & financial statements 2023 Regional Trainee Awards and Best of the Regions In 2023, the Foundation provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons IBAUSI. There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall 'Best of the Regions, would be selected and win a further E500 prize. The overall wnner in 2023 was George Sturges5, a trainee in the Yorskhire & Humber region, for his paper on Ketamine Uropathy- Clinical Experience in a High Prevalence Centre. George was invited to present his paper at the International Continence Society meeting taking place in Toronto. Support for robotic surgery training Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills Useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy's Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures an videos with hands-on robotic surgery practice. Supporting Advanced Consultant Training TUF funded the Advanced Urology Slmulatlon Boot Camp course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role and provides training in often overlooked area5 such as dealing wth 5tre55, effective leadership and the day-to-day challenges of consultant practice. The course was extremely well attended and received. Support for travel and attending conferences and educational programmes During the year a number of small grants were made to urologists and nurses to travel to, or attend, training courses or conference5. Further small grants were also made for researcher5 to hold meetings with patients and stakeholders to understand further the impact of particular disease condition5. Training and education As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions throughout the year on a range of tOPlC5. Highlights included: Working with Knowlex, who proYTde healthcare leaders and commissioning organisations with a range of resources, we took part in their 2023 Infection Prevention and Control Conference in Bimiingham. This is Europe's largest Infection Prevention and Control Conference. TUF Trustee and Consultant Urologist Roland Morley presented on the subject of UT15. We were also invited to run a webinar in March on the topic of "Female Urinary Incontinence Pathways: Where do they lead?" which brought together Mary Garthwaite ITUF'S Chairl, Mehwash Nadeem Iconsultant Urological Surgeon at South Tees University Hospltals Trust} and Sarah Hillery IPresident of British Association of Urological Nurses). We were delighted to attend the British Association of Urological Surgeons IBAUSI Annual Conference in Birmingham and the British Association of Urological Nurses IBAUNI Annual Conference in Edinburgh. Both events provided the opportunity to meet with urology colleagues and industry. TUF'S Chair was inwted to speak at the Convatec Continence Care Customer Symposiurn in November which was attended by urology nurses, continence professionals, GPS and Convatec staff. TUF'S Chair presented two sessions- 'The work of The Urology Foundation, and 'Patient choice in self-catheterisation care,. 14 The Urology Foundation annual report & financial statements 2023 4. Improving public awareness of urological cancers and conditions The Urology Foundation is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience. In April we hosted a Parliamentary Reception together with the Urology Trade Association IUTAI titled 'Keeping patient choice at the heart of NHS and MedTec reform" at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy makers and industry attended the event. In July we partnered with the MS Trust and the Spinal Injuries Association ISIAI to host a unique parliamentary event aimed at raising awareness of the challenges faced by people who use urinary catheters and encourage policy makers to talk about catheters and bladder issues. The event at the Churchill Room, House of Commons saw Parliamentarians participate in the Catheter Care Challenge. an escape-room style 'challenge', competing against colleagues to access a toilet, answering quick- fire questions about catheters and ultimately racing against the clock to complete the quiz and 'catheterise' safely. Paul Bristow MP hosted the event and we were joined by Parliamentarians including Sarah Owen MP (Labl, Margaret Ferrier MP Ilndependentl, Christina Rees MP Ilndependentl, Anna Firth MP Icon), Diana Mary Warwck and Baroness Warwick of Undercliffe ILabl- Sincere thanks to Coloplast for their support with the project. "Help Us, Help You" A highlight of the year was the OPFX)rtunity to take part in the NHSE Cancer Programme's abdominallurological 'Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee" These community-ba5ed events - held at indoor venues such a5 libraries, football stadiums and shopping centres - encouraged visltors worried by a 'blood in pee" symptom to visit their GP or seek an early intervention. There was a particular focus on targeting black and minority ethnic groups, people from socio-economically deprived communities and people with other co- morbidities. In conjunction with the charity UCARE events were held across Oxfordshire and the London Boroughs of Newham and Tower Hamlets. London based events included Stratford Library J Better Gym, the Ideas Store and the East London M05que. Roundtoble Events This year our CEO was invited to participate in a number of Roundtable discussions. Highlights included: In September she attended a cross-party Parliamentary Roundtable at the House of Commons 'Harnessing innovation to address challenges in prostate cancer care" which brought together key stakeholders to discuss how the UK can better use innovations in diagnosis and treatment of prostate cancer to improve patient care. Guests included prostate cancer clinicians and patient group representatives. In October she attended the "Overcoming Inequalities in Cancer Care" a Parliamentary drop- in event organised by Pfizer. The event provided an opportunity for Parliamentarians, clinicians and cancer charities to discuss the regional inequalities that exist in access to cancer care. Further discussions and activities are planned to look at ensuring patients and their families have better outcomes and experiences. Campaigns Throughout the year we took part and supwrted a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include- 15 The Urology Foundation annual report & financial statements 2023 A campaign during Men's Health Week in partnership with Male Health platform TRTed to raise awareness of the underlying symptoms of Erectile Dysfunction and encourage men to talk about this issue. The campaign included a survey and the launch of a new Factsheet written by Mr Hussain M Alnajjar, Consultant Urological Surgeon and Andrologist, Honorary Associate Professor at University College London IUCLI. As part of World Continence Week 2023 we worked with Convatec to develop a series of posters to highlight continence issues, to challenge the stigrna and tab(x) that surrounds incontinence and to encourage people to seek help and support. Urology Awareness Month September is Urology Awareness Month, an annual campaign which brings together our urology community - researchers, urologists, nurses and allied health professionals, influencers and decision makers, patients and their familie5 and those with an interest in urology health to raise awareness of urological cancers and condition5. This year's theme was bladder health with a particular focus on urinary tract infections IUTIs1, urinary incontinence and bladder cancer. Throughout the Month we highlighted stats and facts on bladder health alongside launching new videos, delivering webinars, Roadshows and health and well-being sessions. Highlights included: Knowlex Invited TUF to run a webinar to mark the Month. TUF's Chair, Mary Garthwaite, together with TrLJStee and Consultant Urologist Roland Morley) President of BAUN Sarah Hillery and Locum Consultant Urological Surgeon Yasmin Abu Ghanem, presented a webinar 'Bladder Health: The Hidden Issue.. The webinar examined managing an overactive or under active bladder, the burden of Ljrinary incontinence, bladder cancer and urinary tract infections IUTlsl. Over 600 people registered for the event. Asda supermarket chain supported our London based Roadshows inviting customers and staff to learn about urology health. Together with Network Rail we were able to reach thousands of people through our health messages on their public notice boards at Manchester Piccadilly Station, Kings Cross Station and Liverpool Lime Street Station during September. We also had messaging on payroll slips that reached over 40,000 ernployees. TUF Chair, attended wellbeing sessions for Network Rail employee5 to highlight the signs and symptoms of urology conditions, including prostate cancer. TUF'S Chair took part in a podcast on 'Why urology awareness matters.. This was part of Coloplast Professional's 'Stoma and Continence Conversations, podcast. People were inwted to support the campaign by holding events, posting messages of support on social media, displaying posters and given talks about urology health. In the media 1 in 2 of us wll be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life alongside raising awareness of The Urology Foundation and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highglights included an interview on Radio 4 Woman's Hour on the subject of UTIS and the proposed changes to prescribing - wa the pharmacy setting - for uncomplicated UTIS. In June our Chair was interviewed on popular television show, Steph's Packed Lunch on the subject of male incontinence. As part of Men's Health Week, an erectile dysfunction campaign with the Men's Health platform, TRTed saw coverage in the Daily Mail, Huffington Post and Daily Star online. 16 The Urology Foundation annual report & financial statements 2023 Appointment of the Director of Communications and Policy In November the charity appointed its first Director of Communications and Policy, Laura Thorne. Laura has over ten years, experience in public affairs and communications, implementing national and local change, providing strategic advice and delivering targeted, awareness-raising campaigns. Prior to joining The Urology Foundation, she was Head of Health Public Affairs at a communications and marketing agency. Her expertise includes public affairs and policyi Strategic campaigns- communications- issues management. and relationship building across Westminster and the devolved nations. She has worked collaboratively with pharmaceutical and MedTech companies, charitie5, patient groups, All-Party Parliamentary Group5 and trade bodies to deliver positive change. She is a member of the Cancer52 Policy and Public Affairs Steering Group where she works to improve outcomes for people experiencing less common urology cancers. With over three years, experience working for a Member of Parliament, she also has a strong understanding of the workings of Parliament and Government. 5. Collaborations and partnerships We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partner5 working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Research UK, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and Ucare. We welcomed the opportunity to meet and work wth a range of cornpanies including Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Janssen, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health. 6. Investment in our Team Developing our people and infrastructure is vital as it underpins the delivery of our charitable and fundraising activities. The Trustees have committed to infrastructure investment which wll support sustainability, effectiveness, collaboration and impact particularly within the charity's programmes and grants portfolio which has expanded significantly over the last two years, across fundraising and the expansion of funding streams and to ensure we have a "voice" within the urology community - in driwng change, improving outcomes and patient care. The first stage of the investment saw the appointment of Laura Thorne a5 the new Director of Communications and Policy in November. Two new roles have been approved and recruitment will commence in January 2024: Fundraising Manager (Events and Individual Giving) to manage and expand a portfolio of events, to develop an individual giving programme and to grow the supporter base. Grants & Programmes Executive to support for the growing programmes and grants portfolio 7. Plans for the future Our strategy "The Way Ahead 2023-2025" has set out a clear direction and our ambitions for the next three years. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders, in 2024 we will look to: Launch a new Research Strategy outlining how we will accelerate the progress and breakthroughs in urological research, the key disease area we will focus on and campaigning for further investment in research. Support our urology community and allied healthcare professionals through training and education, study and travel awards and other opportunities. 17 The Urology Foundation annual report & financial statements 2023 Launch a UTI Programme to include a dedicated research grant call to better understand UTIS, a nurse-led UTI Information Service and training for health professionals. Develop a Communications Strategy to Raise awareness of urology health and the work of The Urology Foundation Drive change in urology care and practice through our policy work, campaigning and health awareness initiatives Strengthen our partnerships This will include the launch of a new website, information and promotional resources, media relations and our annual Urology Awareness Month campaign which will focus on Men's Urology Health. Give a voice to the people affected by or at risk of urological disease ensuing they have the opportunity to be heard, to influence and drive change. We will look to SUPPOrt and develop closer relationships with seldom heard communities, those at greater risk of specific disease and those with poorer outcomes. Build on our current work and achievements in prostate cancer, UTIS and bladder heath. Invest in our fundraising programme with the launch a Fundraising Appeal to support the delivery of our new Research Strategy 18 The Urology Foundation annual report & financial statements 2023 Financial Review Financial Results of Activities & Events Assets & Income: 2023 vs 2022 3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 li Net assets Voluntary income Event income 2023 ll 2022 The total value of net assets held by The Urology Foundation on 31 December 2023 was £3,111,987 12022 C2,640,3411. The Foundation's fundraising activities and other initiatives during the course of 2023generated a total of £1,384,437of voluntary income 12022 £1,318,353) and a further £66,80012022 £30,980) from specific fundraising event income. Fundraising The Foundation is reliant on voluntary income to fulfil it5 remit. Following a review of the charity's fundraising function in 2022, the decision was made to invest in this area in order to diversify the existing income streams and to look to increase the charity's income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. We are pleased to report income for year totalled £1,470,272 against the previous year total of 11,355,713. The following information summarises the various disciplines.. Donations. Income f rom donations totalled £136,210. Our sincere thanks to everyone who has supported us during the year. Business Community. We are committed to working with a wide range of companies including those in the pharmaceutical and Med tech industry in order to meet our objectives. Under the direction of Lucy Noakes, our Business Development Manager we have significantly grown this area during the year alongside building and strengthening our existing relationships. With our partners we are raising awareness of urological cancers and conditions and driving change to ensure better outcomes for patients and their families. Highlights during the year include, partnering wth Coloplast on the Catheter Care Challenge at the House of Commons which saw Parliamentarians participate in the Catheter Care Challenge. For World Continence Week we collaborated with Convatec and together challenged the taboos around continence calling for people to foster more openness around the impact it can cause to quality of life. We hosted a Parliamentary Reception together with the Urology Trade A550Clation IUTA Parliamentary Reception 'Keeping patient choice at the heart of NHS and MedTec reform" at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy 19 The Urology Foundation annual report & financial statements 2023 makers and industry attended the event. Reaching different audiences is a key objective for us and last year we were delighted to partner with Network Rail Wellbeing champion to deliver urology focussed webinars for employees, with a special focus on men's health in urology. Looking ahead to 2024, we will further develop our relationship and look to explore new ones to help us grow and deliver more exciting projects. We are grateful for the generosity of our many corporate partners who continue to SUPPOrt our vital work. Trusts and Foundations. Income from a range of both small and large trusts and foundations totalled £1,248,227 and included support toward5 research, awareness, community-based projects, edLJcation and training. This included a grant from The UK Government Covid Medical Research Support Fund totalling £282,018 towards helping to sustain early-career researchers supported by medical research charities impacted by the COVID 29 pandemic. Events. We are pleased to report that supporters organised and took part in a wde range of events throughout the year. These included the TUF Trek to Namibia which saw our President Professor Roger Kirby and Trustee Roland Morley together with eight TUF supporters raise an incredible £65,000. The Great North Run saw five dedicated runners, led by Jo Creswell President of BAUS, take to the streets of Newcastle to raise £3,762. The ever popular London Landmarks Half Marathon ILLHMI saw five runners take to the streets of London to raise an incredible £4,664. Ride London cyclists raised over £2,000 and a Rock Choir Concert organised by supporter Anne Stotesbury raised £2,000. A highlight of 2023 was the Bike4TUF, London to Paris Cycle Ride, in June. This year marked the 10th anniversary of this Fx>pular and successful Bike4TUF Ride organised by consultants Ben Eddy, Ben Challacombe and TUF supporter David Plummer. An incredible £56,650 was raised for TUF. We are grateful to everyone who undertook various fundraising challenges for the charity We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising IloFI and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that ig reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise fund5 for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries Out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback. Reserves & Liquidity Policy The Foundation currently has 'free reseNes' of £2,213,621 131 December 2022: £2,084,596). Our free reserves relate to un-designated unrestricted reserves. During the next financial year, the Trustee5 intend to transfer funds from unrestricted funds to designated funds. The Foundation's policy 15 to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to lil minimise the risk associated with a temporary or unforeseen shortfall in liquidity. lill manage its cash and investments to meet its liabilities and remain a going concern for at 12 months in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of £500,000 I'minirnum Required Reserve") subject to future modification by the Finance Committee and Trustees, approval. The Trustees consider that reserves held in excess of the amounts required to fund all future commltments together with the initial fund of É500,000, will be available to Increase its Vlsibility and expand its operations including funding for further research and a wider range of projects. The Trustees plan leve15 of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as Utilising restricted funds. 20 The Urology Foundation annual report & financial statements 2023 Statement of going concern The Foundation's unrestricted net funds generated in 2023 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year. Investments Policy The Foundation's investments are managed by Rothschild Bank ICII Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually. The Board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 1.4% return over 2023. All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc. Remuneration policy In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy Should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support andlor deliver the charity's aims. It a150 conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living. Pensions policy The charity offers a stakeholder pension, operated by The People's Pension IB&CE Holdingsl, in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired. Equal opportunitles and dlverslty policy The charity is committed to being an Equal Opportunitie5 employer and to respecting diversity. and is determined to ensure that no Job applicant, employee, or trustee receives less fayourable treatment on the grounds of their age, disabilityi gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment. The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment wth the Foundation. The policy also applies to third parties such as Trustees and committee volunteers, clients li.e. grant applicants) and suppliers. Principal risks and uncertainties The Trustees take the management of rrsks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly miti£ated on a regular basis. The potential risks have been discussed with the Chairrnan and the charity and a formal risk register 15 kept, updated and discussed by the Board of Trustees on a quarterly basis. 21 The Urology Foundation annual report & financial statements 2023 Impact of wor in Ukraine ond economic outlook The ongoing war in Ukraine and wider economic outlook has broader economic iwnplications, some of which wll be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action. Risks to Data The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that Stores all information in the cloud and this is secured LJ5ing a two-step pa55word verification. We review our record5 on an ongoing basi5 and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain). Other key risks are assessed as follows- Govemance IEnvironmental Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations,. Data Protection Regulations. TUF is reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing 50 to accept an appropriate level of risk in order to raise income from a wide range of sources. The charity uses a professional database provider that stores all information in the cloud and thi5 15 secured using a tWO-Step password verification. The charity's own day to day working documents are also stored on a cloud-based Sygtem. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches. The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place. TUF'S success is directly related to the amount of resource it can devote to it5 objectives, so the key risk identified by Trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other Trustees. Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employee5 are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People. Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders. To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance. Income Sources Risk of data breach Key Person risk Investment Risk Risk to Employees Risk that research fails to deliver results Loss of Records 22 The Urology Foundation annual report & financial statements 2023 Structure, Governance & Management The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable actiwties of the British Urological Foundation IBUFI, an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009. Charity Governance Code The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting. Trustee Recruitment, Training and Induction The Foundatlon seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee Isee below) are recruited through calls in industry publications. All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary Sector, healthcare and medical research issues. Trustees contribute to every aspect of the charity.. governance; fundraising; financial planning., management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertlse and networks whenever they are called upon. Appointment & Election The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year temi. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees. Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons IBAUSI and one nominated by British Journal of Urology International IBJUII. All other trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the trustees present andlor voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees. The representative trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years. The Executive Team The Chief Executive, is responsible for the day-to-day management of the charity. The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the board of trustees and sub-comrnittees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees: Scientific and Education Committee ISEC) The SEC 15 resFX)nsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. 23 The Urology Foundation annual report & financial statements 2023 The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is rnade up of clinical and academic urologists and scientists th an interest in urologyi and lay representatives. Reseorch Review Panel The Research Review Panel is responsible for assessing application5 for our major research grants and marking these according to the requisite criteria being met. In this task it as51StS the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical tru5tee5 and academic urologists and scientists with an interest in urology. Membership of the SEC and Rewew Panel can be viewed on the charity's website. They provide their services as volunteers and we are enormously grateful to them. Finance Committee The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Mewnbership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts. IT Oversight C(xnmittee The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustee5 on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer. Relatlonshlps w1th Related Partles The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees. Representation on Other Bodies The charity is a member of the Association of Medical Research Charities IAMRCI, which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research INIHRI non- commercial Partner. Thi5 means the Studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network. The charity is also a member of Cancer 52, Charities Research Involvement Group, the National Council for Voluntary Organisations INCVOI and UNSEEN, a UK leading anti-slavery charity working with survivors, bu5ine55es, governments, tx)lice and NHS to end slavery. 24 The Urology Foundation annual report & financial statements 2023 Reference and administrative details The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee. Trustee5 Ms Mary Garthwaite (Choir) Ms Angela Daniel ITreasurerJ Mr Mark Becker (Secretary) Prof Grant Stewart Ichair, SEC re5isned 14 March 2023) Prof Rakesh Heer (Chair SEC, appt 14 hlarch 2023) Ms Hilary Baker (appt 21 March 20241 Mr Mo Belal lappt 21 March 2024 Mr Ben Challacombe Ms Jo Cresswell Iresigned 17 June 2024) Mr Mike Griggs (appt l Jonuory 20231 Mr Adrian Joyce {resigned 8 December 2023) Prof Alan McNeill (appt 10 Feb 2023) Mr Roland Morley Iresisned 2 1 March 2024) Mr Kieran O'Flynn lappt 8 December 2023) Mr lan Pearce (appt 17 July 2024) Ms Julia Taylor (appt 21 March 2024) M5 Hannah Warren Chief Executive M5 Rebecca Porta Registered Office 1-2 St Andrew's Hill London EC4V 5BY Charity number 1128683 IEngland & Wales) Company number 06817868 Auditors Dunkley & Co Ltd Woodlands Grange, W(x)dlands Lane Bradley Stoke Bristol BS32 4JY President Prof Roger Kirby Patrons Mr Handel Evans Sir Ranulph Fiennes OBE Mrs Rosemary Macaire Ms Jane Macquitty MBE Mr Steven Norris Bankers National Westminster Bank plc PO Box 2022 10 Marylebone High Street London W1A 1FH Investment Manager Rothschild Bank ICII Limited St. Julian's Court, St. Julian's Avenue St. Peter Port Guernsey GY1 3UA Ambassadors Mr Alex Corbisiero Mr Stephen Fry Mrs Kate Holmes 25 The Urology Foundation annual report & financial statements 2023 Trustees, & Directors, Responsibilities in the Preparation of Financial Statements The trustees (who are also the directors of The Urology Foundation for the purposes of company lawl are responsible for preparing the trustees, Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practicel- Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to- select suitable accounting policies and then apply them consistently> observe the methods and principles in the Charities SORP., make judgements and estimates that are reasonable and prudent., state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and prepare the financial statements on the going concern basis unle55 It is inappropriate to presume that the charitable company will continue in business. The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply wth Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are resFX)nsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions. Auditor Mr Matthew Dobbins IFCAI, of Dunkley & Co Ltd. has agreed to act as Auditor. Statement as to dfsclosure of Informatlon to the audltor The trustees and directors at the date of approval of this trustees, annual reFX)rt confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor 15 unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information. 67kthwai.te Mary Gart aite (Sep 26, 2024 17..27 GMT+ll hlary Garthwaite, Chair Date: 26109/2024 26 The Urology Foundation annual report & financial statements 2023 Re ort of the Inde endent Auditors to the Trustees of The Urol Foundation 1Stered number- 06817868 Opinion We have audited the financial statements of The Ur01￿Y Foundation Ithe'charitable company I for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdotn Accounting Standards (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements: give a true and fair view of the state of the charitable companys affairs as at 31 December 2023 and of its incotning resources and application of resources, including its incotne and expenditure, for the year then ended; have been property prepared in accordance wth United Kingdom Generally Accepted Accounting Practice., and have been prepared in accordance with the requirements of the Companies Act 2CK)6. Basls for oplnlon We conducted audit in accordance with International Standards on Auditing IUKI IISAs IUKII and applicable law. Our re5POn5ibilitie5 under those standard5 are further described in the Auditors. responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit ewdence we have obtained fs SLrfficient and appropriate to provide a basis for our opinion. Conclusions relating to goin8 concern In auditing the financial statements, we have concluded that the tru5tees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively. may cast significant doubt on the charitable companys ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for 15sue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. Other Informatlon The trustees are responslble for the other informatlon. The other Information comprises the informatlon included in the Annual Report, other than the financial statetnent5 and our Report of the Independent Auditors thereon. Our opinion on the financial 5tatement5 does not cover the other infortnalion and, except to the extent othe￿7$e explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial Statements or our knowledge obtained in the audit or otherw5e appear5 to be materially mi55tated. If we identify such tnaterial inconsistencies or apparent tnalerial tlli55tatetnent5, we are required to detertnine whether this gives rise to a tnaterial misstatement in the financial staletnenls thern5elves. If, based on the work we have perforrned, we conclude that there 15 a material rrisstatement of this other information, we are required to report that fact. We have nothing to retx)rt in thi5 regard. Matters on whlch we are requlred to report by exceptlon We have nothing to report in respect of the folltswing matters where the Charities (Accounts and Reportsl RegulatlOn5 2008 requires u5 to report to you if, in our opinion.. the infortnalion given in the Report of the Trustee5 is inconsistent in any tnaterial respect wth the financial staternents. or the charitable company has not kept adequate accounting records. or the financial statement5 are not in agreement with the accounting records and retums,. or we have not r￿e1Ved all the information and explanations we require for our audit. 27 The Urology Foundation annual report & financial statements 2023 Re ort of the Inde endent Audltors to the Trustees of The Urolo Foundation istered number: 06817868 Responsibilities of trustees As explained more fully in the Statement of Trustees. Responsibilities, the trustees Iwho are also the directors of the charitable company for the purposes of company lawl are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. and for such internal control as the trustees determine is necessary to enable the preparation of financial statements Lhat are free from rnaterial tni5Statetnent, whether due to fraud or error. In prepaNng the financial statement5, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operation5, or have no realistic alternative but to do 50. 28 The Urology Foundation annual report & financial statements 2023 Re ort of the Inde endent Auditors to the Trustees of The Urolo Foundatlon R Istered number: 06817868 Our rèsponsibilities for thè audit of the financial statèmènts We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or hawng effect thereunder. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, bLJt 15 not a guarantee that an audit condLJCted in accordance with ISAS IUKI Mll always detect a rnaterial misstatement when it exists. Misstatements can arise frotn fraud or error and are considered tnaterial if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial staternents. Irregularities, including fraud, are instances of non-compliance with laws and r￿uLations. We design procedures in line with our responsibilities, Outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.. Extent to which the audit was considered capable of detecting irregularities, including fraud We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a ba515 for our opinion. Identifwng and assessing potential risks related to irregularities In identifying and assessing risks of material misstatement in respect of irregularitie5, including fraud and non-compliance with laws and regulations, we considered the following.. The nature of the charitable sector, control enwronrnent and performance including the design of the organisation's rernuneration policie5', Any Matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to: o Identifying, evaluating and complying wlth law5 and regulatlons and whether they were aware of any instances of non-cotllpliance,. o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud., o The Internal controls estsblished to mltlgate ￿Sk5 of fraud or ntsn-compllance with la￿ and regulations., o The rnatter5 discussed among the audit engagernent tearn regarding how and where fraud rnight occur in the financial Statements and any potential indicators of fraud. As a result of these procedures, we considered the opportunities and incentives that may exist wthin the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls. going concern, income recognition, and the appropriateness of expenditure. We also obtained an understanding of the legal and regulatory framework that the organisation operate5 in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. Audit response to risks identified Our procedures to respond to risks identified included the following.. Enquiring of management, conceming actual and potential litigation and claims. Substantive testing to vouch source records to the financial statements,. Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud. 29 The Urology Foundation annual report & financial statements 2023 Re ort of the Inde endent Auditors to the Trustees of The Urolo Foundatlon R Istered number: 06817868 Enquiring of rnanagernent Lhe internal contro15 in, evalLJating each control for weakness and vouching to evidence of the control taking place,. In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments., assessing whether the judgements made in making accounting estimates are indicative of a potential bias-, and evaluating the business rationale of any significant transactlOn5 that are unusual or outside the normal course of bu5ines5. We also comrnunicated relevant identified laws and regulations and potential fraud risks to all engagement team rnembers, and rernained alert to any indications of fraud or non-cornpliance with laws and regulations throughout the audit. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reportins Council's website at www.frc.org.uklauditorsresponsibilities. This description forms part of our Report of the Independent Auditors. Use of our report This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2(K)8. Our audit work has been undertaken so that we might state to the charitsble company's trustees those matters we are required to stste to them in an auditors, report and for no other purpose. To the fullest extent perrnitted by law, we do not accept or ssume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this retx)rt, or for the opinion5 we have formed. Matthew Dobbins FCA Dunkley5 Chartered Accountants Registered Auditor5 Eligible to act as an auditor in terms of Section 1212 of the Cornpanies Act 2006 Woodlands Grange Woodlands Lane Bradley Stoke Bristol BS32 4JY 2610912024 Date: 30 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM STATEMENT OF FINANCIAL A￿1VITIEs for the year ended 31 December 2023 Unre5tri£ted Funds Restricted Funds Total 2023 Total 2022 N¢xe INCO DonatlOn5 and legacie5 Other trading aciivitles Investments 140.195 66,800 19,035 226,030 1,244,242 1,384,437 66.800 19,035 1,470,272 1,318,353 30,980 6,380 1,355,713 TOTAL INCOME 1,244,242 EXPENDtruRE Raising Fund5 Donatlons and legacles Trading aCti￿[leS Investment mana8etnent C05t5 24.761 21,357 78 35,852 37,315 78 43,308 42,830 74 15,959 Expendlture on Charltable actI￿lIeS Raising Awareness Grant maklng 82,382 198,193 54,753 879,886 1.078,079 680,136 Net I0￿e5/{GaIns> on investment a55et5 1289,4711 255,897 TOTAL EXPENDITURE 37,300 961,326 99B,626 1,163,256 INCOMEI{EXPENDITUREI 188,730 282,917 471,646 192,457 RECONCILIAllON OF FUNDS Fund balance5 brou8ht forward ai 1 January 2023 2,084,597 555,744 2,640,341 2.447,884 Transfer between fund5 (s9,7￿) 59,706 FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2023 2,213,621 898,366 3,111,987 2,640,341 The net movement in funds for the year anse5 from the charitys continuing operations. No separate statemeni of total changes in equily has been presented as all such gains and losses have been dealt with In the staiement of financial aciivities. The notes on pogts J5 to 44 form port of these occounts 31 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM STATEMENT OF FINANCIAL ACTIVITIES for the year ended 31 December 2021 (Full fund compararivel Unrestrfcted Fund5 Restrfcte Funds Total 2022 Note INCOAIE Donations and I￿a£le5 Other trading artiwtie5 Inve5tment5 TOTAL INCOME 1,016,BB1 30,980 6.380 1,054,241 301,472 1,31B,353 30,980 6,380 301,472 EXPEND￿uRE Ralslng Funds Donations and I￿a(leS Trading actiwties Invesiment managetteni costs 38,978 38,547 74 4,330 4,283 43,308 42,830 74 Exppnditure on Charitable ac￿￿tieS Ra1sing Awareness Grant making 126,910 606,675 73,461 680,116 Nei (Gains) on invesiment assets 255.571 320 255,897 INCOMEIIEXPENDITURE} 1,066,761 96,495 1,163,256 NET (ExPEND￿UREl 21)4,977 192,457 RECONCILIAnON OF FUNDS Fund balances broughl forward at 1 January 2022 2,097,116 350,768 2,447,884 Transfer beiween funds FUND BALANCES (ARRIED FORWARD AT 31 DECEMBER 2022 2.084.596 555 745 2.640.341 The net movement in fund5 for the year arise5 from the charity'5 continuing operations. ND separate statement of total changes in equity has been presented as all such gains and losses have been dealt Mth in the statement of financial acti￿tIes. Tre notes on pages 35 ro 44 form port or these occoynrs 32 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATIOM BALANCE SHE as at 31 Decernber 2023 Company Number 06817868 2023 2022 Note FIXED ASSETS Tangible assets Investments 10 3,895 3,453,644 2,719 3,4D7,104 3,457,540 3,409,823 CURRENT Asstrs Debtor5 Cash at bank and in hand 12 440,181 415,083 413,449 322,606 855,263 966,337 736,055 1.102,738 LIABILITIES: amounts falllng due wlthln one year 13 CURRENT LIABILITrEg 1366,6831 LIABILITIES: am￿nts falllng due In more than one year 234,479 402,799 ASSEfs 3,111,987 2,640,341 THE FUNDS OF THE CHARrrY Restricted income fund5 Robot1¢ Surgery Tralning Fund Pr051ate Cancer Research Fund Bladder Cancer Fund Travel Fellowship Fund Team Corbs- Testicular Charle5 Reynolds Thompson Family Charitable Trust Innovation & Research Awards Small Research Projects CaTnpaign5 Evenis Total Restricted Income funds Unrestricted income fund5 General Fund Designated Fund (British Ur01￿Y Foundation) TOTAL CHARrrY FUNDS 106.448 20B,149 344,862 160.170 137,269 184,851 648 7,313 13,002 126,556 85,197 65,497 6,839 898,366 555,744 1.584.597 500,000 2,640,341 s￿,000 3,111,987 16 These financial siaiements have been prepared In accordance Mth the special prDvisions of Part 15 of Lhe Companies Act 2CKkn relating to Small charitable companie5 and h?th the Financial Reporting Standard 102. The financial statements on page5 25 to 28 were approved by the trustees and authorised for Issue 20 September 2024, and are signed their behalf by Treasurer ry Garthwalte geia Danlel The J)otes on pages 35 to 44 form port of these Gccounts 33 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM STATEMENT OF CASHFLOWS as at 31 DÈ¢embèr 2023 Z023 2022 Note 14 CASH FLOWS FROM OPERATING A(nV￿1Es.. Net cash used in operatini acbrftles 84,134 Cash flows from investing actiwties.. Dividend5 inlere5l froTn inve5lments Management fees paid frcrm Investments Purchase of equipfflent TraD5fer froTn cash Proceeds from sale of lnves1m￿Is Purchase of investments 14,039 5,855 150 15,8821 1307,8331 Net cash used In Investlng artI￿lIeS.. 255,399 Change in cash and cash equivalents in the reporting peri Cash equivalents al Ihe beginning of Ihe reporiing period Cash and cash equivalents at the end of the reporting period 92,477 322,605 415,083 84,185 238,420 322,605 The note5 on pages J5 to 44 form part o[ these acciwnts 34 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION Flnanclal statements for the year ended 31 December 2023 ACCOUNTING POLICIES BASIS OF ACCOUNTING The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance wth the Statement of Recommended Practice.. Accounting and Reporting by Charities preparing their accounts in accordance wth the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdotn and Republic of Ireland IFR5 1021 and Charitie5 Act 2011. The trust constitutes a public benefit entity as defined by FRS 102. INCOME Grants, donation5 and other 5irnilar types of voluntary incotne are brought into account when it 15 probable that they will be received, except that donated income 15 included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income. Income receivable from actlylties for generatlng funds and from investment income Is accounted for on an accruals basis. Deferred income represènts revenues collected but not earned as of 31 Decetnber 2023. This is pritnarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place. EXPENDITURE Resources expended are allocated to the costs of generating funds or to the charitys principal activity where the costs can be identified as being directly related. All other costs are categ0ri5ed as either support Costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the Cost involved. Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are reC￿nISed and deferred where there is a long term commitment for the Charity. Where grants are recogni5ed and condition5 for sta8ed grant paytnent5 are not met In 5ub5equent years, an adjustment to grants payable will be tnade in the relevant accounting period. Expenditure include5 irrecoverable VAT which is reported a5 parl of the expenditure to which it relate5. TANGIBLE FIXED ASSETS All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified a5 fixed a55et5. Tangible fixed as5et5 are stated at historical c05t le55 depreciation. Depreciation 15 provided on all tangible fixed assets at rate5 calculated Lo write each asset down to its estimated residual value evenly over its expected useful life, as follow5.. Office equipment 25% reducing balance OPERATING LEASES Renta15 under operating leases are charged to the Statement of financial activilie5 on a straight line basis over the lease term. 35 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION Flnanclal statements for the year ended 31 December 2023 ACCOUNTING POLICIES INVESTMENTS The charity's investments are included in the balance sheet at their market value. The gain5 tsr ltssses arising upon their annual revaluation are included in the staternent of financial actiwties. FUND ACCOUNTING The general fund comprises the accumulated surpluses of unrestrfcted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity. Designated funds are a particular forrn of unrestricted fund5 con51Sting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees. Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward In the balance sheet. FOREIGN EXCHANGE Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs. GOING CONCERN The Trustee5 as Director5 of the Charity believe that there are no tnaterial uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st Decernber and the forecast incorne expected in 2024. FINANCIAL INSTRUMENTS The charity only ha5 financial as5et5 and financial liabilities of a kind that qualify a5 basic financial instruments. Basic financial instrument5 are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loan5 which are subsequently measured at amortised cost using the effective interest methcmj. 36 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM NOTES TO THE FINANCIAL STATEIIENTS for the year ended 31 December 2023 Unrestrfcted funds Restrfcte funds 2023 2022 INCOhlE FROM DONATIONS AND LEGACIES Grants recelved from charltable trusts and corporate sponsors Donation5 acie5 28,9B5 1,119,242 25,000 1,24B,227 136,210 929,835 388,518 140,195 1,244,242 1,384,437 1,318,353 INCOME FROM OTHER TRADING ACTIVITIES Income from fundrai51ng events 66,800 66,800 30,980 INVEsfAIENT INCOME Bank interest receivable on short term cash de￿ts Income from Investments 11sied on a recrynised stock exchange.. UK investments Overseas Investments 4,996 4,996 525 14,039 14,039 5,855 19,035 19,035 6,380 COSTS OF PAISING FUNOS VOLUNTARY INCOME rect costs 5upp)ri cosis (see nore 81 18,664 24,644 19,530 10,509 3Q,040 24,761 35,852 43,308 37 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2023 Unrestricted Restricted funds funds 2023 2022 COSTS OF RAISING FUNDS TRADING ACTIVITIES Costs of fundraising events Support C05t515￿ note 81 1,826 19,530 5,449 10,509 7.276 30,040 18,186 24,644 21,357 15,959 37,315 42.830 COSTS OF RA151NG AWARENE55 Costs of fundraislng events Support Costs (see note 81 4,261 78,121 12,715 42,038 16,976 120,159 42,433 98,578 82,382 54,753 137,135 GIiINT MAKING Innoyatlon & Reswth Award 435,592 143,304 120,WO 55,759 435,592 143,304 120,0(MJ 55,759 iROC BkdderCan(er Trial 12,3421 Davil Thtythpsofft Fellowship small Rosèarch Projects awarded to 6120Z2-. 51 team5 Robotlt Céntr* of fralnlng Re5ear(h ￿holArShIpS awarded lo 38,914 18,938 124.9181 18,938 124,9181 369,082 Urollnk Fe1knI5hlp BAU5 1,493 1,199 9,996 1,415 2,943 26,001 6,1CQ 1,493 1,199 9,996 1,415 3,591 26,001 6,100 4,500 3,032 K•lth Yo6tQ5 mqdats award•d to I 12022.. 51 indI￿dual5 Travel Grartts 10,000 500 647 Olhor dlrect costs BAUN￿UF Nurse 12,0831 39,203 14,449 1,350 42,752 PPI In Res￿￿1patIefftt Patient Advocacy Research Awarene55 (WCW& UAMI Aknemént In presonl valuèol grant ac(rua15 5,824 5,824 54,971 749,321 53,495 77,069 804,292 53,495 220,291 499,409 Salary costs Support cost515￿ note 81 143,222 180,727 198,193 879,886 1,078,079 680,136 38 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION NOTES TO THE FINANCIAL STATEMENTS for thè yèar ènded 31 Detèmbèr 2023 Costs Df Fundrai5in4 ¥eneratini tradiThE= C05t Yoluntary of goods income sold Awarenes5 GI￿nI 8rants 55% 2023 Z022 7.5% 7.5% 8. SUPPORT AND GOVERNANCE COSTS IUNRESTRICTEDI staff costs (see note 91 Oiher siaff costs Including recruiiment Commiiiee and Oiher siaff welfare expènses Oiher Dffice ¢o5ts Audit fee Accountanq and ath5Qry 5eDrice5 Other costs Depreciation-owned assets 9,153 895 345 67,119 6,563 2,532 31,414 1,758 7.556 25.997 282 194,741 3,580 345 4,605 4,010 58,912 4,284 240 1,030 3,545 38 4,284 240 1.030 3,545 38 959 3.196 13,738 47,267 14,180 23,320 19,530 19.530 78,121 143.222 260,403 295.733 8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED Staff costs (see nTrte 91 Olher siaff cttts Includlng retruit￿rnt Commiiiee and oiher siaff welfare expenses OLher office costs Audit lee Actountsnty and ad￿sOry ser￿teS Olher costs Depreciation-owned assets 2.989 292 2.989 292 21.918 2,142 827 40.558 574 2.467 8,489 92 39.851 3,896 1,504 73,742 21.638 347 445 6,546 32 1.170 2,590 451 78 336 78 336 1.346 4,631 167 10.509 77.069 32.859 39 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION NOTES TO THE FINANCIAL STATEMENTS for thè year ended 31 Decèmber 2023 2023 2022 STAFF COSTS No. No. The average monthly number of ￿r$On5 employed by the charity lexcluding Irusteesl during the period was, as follows.. Office and administration Staff c￿ts for the above per50n5'. Staff Wages and salaries Staff so￿aL security costs Key management personnel Wages and salar1es Key management personnel Soaal security costs 105,352 8,376 92,7LKI 8,954 215,382 137,779 13,374 59,655 5,571 216,379 One employee received total emolument5 in excess of E60,000 per annutn during the period ended 31 December 2023 12022.. 21. The tot31 emoluments of these employee5 durine the year were in the following ranges.. 2023 20ZZ £I(N),000- £110,0(N) ll- Jn, 11 £90,(th)- £1￿,000 L60,LW- £70,000 No. The Charity cons1ders1ts key management personnel comprise the Chief Executlve, YAth remunerat1on as noted aboi In setting salary levels, The Urology Foundation foll0v￿ the National Counal for Voluntary Organisation's advi￿ thai tharity's pay pollcy should be to offer fa1r pay to attract and keep apprDpr1ateiy-quallfled staff to lead, manage, 5UPPOrt andlor deliver the charity's aims. It 8150 conducts online research of charity salaries 3nd use5 survey5 to benchmark levels of pay. The Urology Foundat1on does not automatlcèlly award Its sraff YAth annual saLary1ntreasÉ either Incremental or cost of living. No Director received any remuneration from the Company during the year 12022.. Énill. No trustee received any remuneration for 5ervice5 provided to the charity during the current or prewous period. Trustees expen￿ reimbursed In respect of Trustee'5 meetings and travel for the year ended 31st December 2023 atnounted to £0 paid to no Trustee5 12022 £0 paid to no Tru5teesl. 10. TANGIBLE Asstrs Office Equlpment Cosi-. 1 January 2023 Addiiions 22,494 1,856 31 tkcember 2023 24,350 Depreciation.. l January 2023 Charge for year 19,775 680 31 Dectynber 2023 20.455 Net b￿k value.. 31 December 2023 3,895 31 Decernbey 2022 2,719 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION NOTES TO ThE FINANCIAL STATEAIENTS for the year ended 31 December 2023 2023 2022 INVESTMENTS Investmenis Ilsted ￿ a recolnlsed stock exchange at market value.. 1 January 2023 Transfer5 from cash Additions at cost thsposal pr(Keeds Realised gains Unrealised Ilossesllgains 3,407,104 3,657,270 307,833 5,882 29 1255,9261 289,830 31 December 2023 3,453,644 3,407,104 At ihe balance sheei date, the marker value of the portfolio conprised.. UK Investments 3,453,644 3,407,104 3,453,644 3,407,104 Flxed Income secur1lles Multi-Asset & Hybrid Instruments 306,382 3,147,262 549,597 2,857,508 3,453,644 3,407,104 At the balance Sheet date, the h1storlcal c05t of the Investments was c2,7￿,892 12022." £2,944,132). The follovring holding5 had a value of >5% of the market value of the inve5tment5.' Value E 2023 3,147,262 Value C 2022 2,857,508 Name Rothschild & Co WAI SICAV-SIF Exbury Fund GBP Pentairs QIAIF PLC Vanda Fund Sh5-F- USD Shs Institutionalcash 5eriesPLC- BiackRock IC5 Sterling Liquidity Fund Holdir 306,382 549,597 DEBTOR5 20Z3 2022 nts falling due wilhin one year.. Prepayments Accrued Inc(ffle 18,978 421,203 440,181 14,086 399,363 413,449 41 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM NOTES TO THE FINANCIAL STATEIIENTS for the year ended 31 December 2023 CREDITORS 2023 2022 Amount5 falling due within year.. Deferred Income Trade creditor5 General accrvals Grani accruals Other creditors 13,382 150,500 7,183 795,272 504 45,971 1,049,953 6,310 1 102 738 Deferred Incotne blfwd at 1 January 2023 41mounts releasèd in the year amounrs deferred in the year Deferred Income clfwd at 31 December 2023 504 13,382 13,382 CREDITORS 2023 2022 Amount5 falling due in more than year.. Grant accruals 234,479 402,799 234.479 402 799 14. RECONCILIAMON OF INCOMEIIEXPENDITUREI TO NET CASHFLOW FROM OPERATING A￿l￿TIEs Net Incomellexpenditurel for the reporting period per the statement of flndndal acYvl¢les 471,646 192,458 Adjustment5 for.. Depreclatlon charges Lossesllgainsl on investments Idends and interest from inve5trnents Management fees paid from investments Ilncreasel In debiors IDecrea5el in creditor5 907 255,897 1289,8331 78 126,7321 1304,7211 72 1314,7261 144,6191 Net cash used In operatlng acrivltyes 84,134 THE FUNDS OF THE CHARIT 1 January 2023 Gainslllossesl 31 December on Investments 2023 Transf@r Incom Expendltur Restricted irKOTne funds: Robotic Surgery Training Fund Pros131e Cancer Research Fund Bladder Cancer Fund Travel Fellowship Fund Team Corbs- TestlcJlar Charles Reynolds ThotllP50n Family Charitable Trust Innovation & Research Awards Small Research Projects CaTnpaign5 Events 160,170 137.269 153,7651 24.918 43 106,448 208.149 344,862 45.879 359,000 139 16481 7,313 13,002 126,556 85,197 65,497 152,51X)I 300,000 491.614 11,QOO 72.5 51,456 162,4561 25.￿0 6,839 555,744 59,706 1,244,242 1961,6891 362 898,366 Unrestricted income funds.. fjeneral Fund Designated Fund IWFI 1,584,597 500,000 2,640,341 (s9,7(￿) 226,030 1326,7711 289,471 1,713,621 5CK),000 1,470,272 11,288,460> 289,833 42 The Urology Foundation annual report & financial statements 2023 THE UROLOGY FOUNDATION NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2023 15. THE FUNDS OF THE CHARITY Icontlnuedl The TrustÈÈs have designated the origin31 1995 start-up funding for the BUF of £500,OW as the Trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis. The Robotic Surgery Training Fund was set up In I￿9 following the receipt of restricted donation income from the British Urological Foundation and a generous prrivate donation. The funds are mainly used to award grant5 toward5 robotically a5515ted surgery trainin£, education, and research into robotic training techniques. Bladder Cancer Fund.. Thanks to the generoslty of the Champn15s Foundation and the Champniss Charitable Trust, The Urology Foundarion has been able to 5UPPOrt a number of projects, including research project5 tracking patient5, fitne55 Post cancer surgery and to predict complications arising during and p05t Prostate Cancer Research - Thanks to the 5UPPOrt of the John Black Charitable Foundation, The Urology Foundation has been able to suppori a number of projects furthering our Unders￿ndIng of prostate cancer and its treatment5. Two further research grants were awarded in 2023. Team Corbs: The Foundatlon Started working with former England and Lion5 rugby charnpion, Alex Corbisiero, to raise funds for research into iesticular cancèr, following Alex's diagnosis. A Just GivinE page has been set up and the charity will continue to fundraise vrith Alex. Charles Reynolds funds are put toward5 5UPPOrting a nurnber of our research project5 and to support education and rraining for urology nurses, in particular through nurse bursaries and travel grants. The Thompson Family Charitable Trust generously support our charitable aims and objeciiv*, in particular SUPPOrt of research and training, and through funding the David Thompson Fellowships. 2023 was in the inaugural year of the Fellow5hip5 and four awards were made. Innovalion & Research Awards. These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions. Small Research projecis. These awards are pAmar11y about studies that might Improve patient pathways or treatment and care. Projects are worth £10,000 each. Campaigns- As part of the NHSE Cancer Programme's abdominallurological 'Help Us, Help You" symptoms awareness campaign and specifically the symptorn 'Blood in Pee" a seri￿ of community based event5 were deliver￿ across London. Visitors worrièd about 3"blood in peè" symptom wÈr@ @ncouraièd to visit thèir GP or seek an early intervention. Events- The Foundation wa5 pleased to receive support toward5 the TUF Trek to Natnibia. 43 The Urology Foundation annual report & financial statements 2023 THE UROLQGY FOUNDATIOM NOTES TO THE FINANCIAL STATEIIENTS for yèar endèd 31 December 2023 ANALY515 OF ASSETS B￿WEEN FUNDS Fixed Assets Net AssetsiiL1abllltlesl Total Restdcted Income funds: Robotic Surgery Training Fund Pr05tate Cancer Research Fund Bladder Cancer Fund Travel Fellowship Fund Teatn Corbs- Testicular Charle5 Reynold5 Thompwn Family Charltable Trvsr Innovation & Research Awards Stnall Research Projects Campalgns Events Unrestricted irKome funds.. General Fund Designaied Fund (British Urology Foundation) NET ASSETS 106,448 208,149 344,862 231,002 382,723 137,8621 7,313 13,002 126,556 85,197 14,429 140,450 94,550 7,590 6,839 1.901.754 554,893 3,453,6 1.713.621 5(K),000 3,111,987 154,8931 341,658 LILTIMATE cO￿RoLLING PARTY The Charity is controlled by the board of Trust￿. COMMITMENTS UNDER OPERAMNfj LEASE5 As at 31SI December 2023, the Charity had annualised operaLin8 commitments under non-can¢eilable operaring leases explring as follows.. 2023 1012 Expiring within oDe year Land and Buildlngs Others 12,500 10,937 12,500 10,937 Expiring within two to fiye years Land and Buildin95 Others 12,500 12,500 CONMNGENT A5SEf5 There were no contingenr assets as at 31 Decanber 2023. 20. RELATED PARfiTR4NSACTrONS Durin8 the year. travel expen5e5 amounting to £2,257 were reimbursed tD the Tru5tee5. DonatiDn5 of e240 were recelvÈd from the Trustees. ND furthèr iransactlons were underraken such as are required ro be disclosed under 101 or the Charities Act. The Urology Foundation annual report & financial statements 2023